ZEYNEP ERDOGMUS OZGEN

Ms. ZEYNEP ERDOGMUS OZGEN

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Human & Experimental Toxicology
Verified
Journal Article
Open access
ZOZEYNEP ERDOGMUS OZGEN
ZEYNEP ERDOGMUS OZGEN
MEMeral Erdinc
Meral Erdinc
IKİlKer Kelle
İlKer Kelle
LELevent Erdinc
Levent Erdinc
YNYusuf Nergiz
Yusuf Nergiz
Background: Doxorubicin (Dox) is one of the most effective antineoplastic drugs which has severe cardiotoxic effects, limiting its clinical usage. Though the exact mechanism of doxorubicin-induced cardiotoxicity is yet to be elucidated, it is shown that production of reactive oxygen species (ROS) increases oxidative stress and leads to cardiomyocyte apoptosis and necroptosis which is also defined as a programmed cell death. Purpose: In the present study, we investigate the effects of necrostatin-1 (Nec-1)—an inhibitor of receptor interaction proteins 1 (RIP1) and necroptosis—on doxorubicin-induced cardiotoxicity in rats. Research Design: Hearts were isolated and perfused by the Langendorff system in all four groups. Perfusion pressure (PP), left ventricular developed pressure (LVDP) and heart rate per minute (HR), LV (dP/dt) max, and LV (dP/dt) min which shows cardiac contractility and relaxation were recorded. Results: Results showed that PP significantly increased with Dox treatment and significantly decreased with Nec-1 treatment, while HR, LVDP, LV (dP/dt) max, and LV (dP/dt) min values significantly decreased with the Dox-treated group and significantly increased with Nec-1 treatment. Also with Nec-1 treatment, gene expression levels of anti-apoptotic Bcl-2 significantly increased and pro-apoptotic protein Bax, apoptotic marker caspase-3, and Nox-2 significantly decreased compared to the Dox-treated group. In heart tissues, MDA levels were significantly increased with Dox and decreased with Nec-1 treatment. These results were supported by the histological analysis indicated that Nec-1 reduced doxorubicin-induced cellular injury. Conclusions: In conclusion, our data indicate that Nec-1 ameliorates doxorubicin-induced cardiotoxicity by reducing oxidative stress injury and attenuating apoptosis and necroptosis.

4 December 2024 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
ZOZEYNEP ERDOGMUS OZGEN
ZEYNEP ERDOGMUS OZGEN
MEMeral Erdinc
Meral Erdinc
MKMeryem Seyda Kaya
Meryem Seyda Kaya
FAFesih Aktar
Fesih Aktar
SOSelver Ozsener Ozekinci
Selver Ozsener Ozekinci
EUEmre Uyar
Emre Uyar

30 May 2021 in Izmir Democracy University Health Sciences Journal
Verified
Journal Article
Closed access
ZOZEYNEP ERDOGMUS OZGEN
ZEYNEP ERDOGMUS OZGEN
Yüksek antineoplastik aktiviteleri nedeniyle onkolojide en sık kullanılan antrasiklinler arasında yer alan doksorubisin; göğüs, over, testis, tiroid, akciğer kanserlerinde ve birçok sarkomun tedavisinde klinik uygulaması olan önemli ilaçlardan biridir. Ancak doksorubisinin klinik kullanımını kısıtlayan önemli ve ciddi kardiotoksik yan etkisi vardır. Bu derlemede kardiotoksik etki mekanizmasının araştırılması amaçlandı. Araştırma sonucunda kardiotoksisite oluşumunda; nükleik asit ve protein sentezinin inhibisyonu, vazoaktif aminlerin salınımı, mitokondriyal membran potansiyelinde kayıp ve elektron trasport zincirinin inhibisyonu, adrenerjik fonksiyonlardaki değişiklikler, adenilat siklaz, Na+-K+ ATPaz ve Ca+ ATPaz aktivitelerinin azalması gibi mekanizmalar etkili olsa da oksidatif stres ve apoptozisin asıl etken olduğu görülmüştür. Doksorubisinin oluşturduğu kardiotoksisiteyi azaltmaya yönelik koruyucu maddeler araştırmalarda kullanılmış olsa da bu maddelerin klinikte kullanımları yeterli düzeylere ulaşılabilmiş değildir. Yapılan literatür taraması sonucunda, Doksorubisinin oluşturduğu kardiotoksisiteyi azaltmaya yönelik daha ayrıntılı çalışmaların yapılması gerektiği kanaatine varılmıştır.

15 July 2025 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
ZOZEYNEP ERDOGMUS OZGEN
ZEYNEP ERDOGMUS OZGEN
BABarıs Asana
Barıs Asana
MOMuhammed Mansur Ozgen
Muhammed Mansur Ozgen
Objectives: We aimed to investigate the adverse drug reactions (ADRs) observed in cancer patients, the drugs causing ADRs, ADRs reporting rate, common adverse effects, drug interactions, and the drugs used to manage these adverse effects. Methods: A questionnaire about pharmacovigilance, the most common ADRs and side effects observed in oncology patients, the frequency of these ADRs, the drugs causing them, and drug interactions was administered to the volunteers in our study. Results: Although 66 out of the 90 nurses who participated in the study reported having previously encountered an ADR, only 39 of them actually reported it. ADRs were most frequently seen once a year or more and 56% of the ADRs were life-threatening, 21% medically important and 23% resulted in hospitalization. The pharmacological groups with the most ADR reports were; Taxanes, Platinum compounds, Monoclonal antibody (Mabs), Antimetabolites, Alkylating agents, Topoisomerase inhibitors and alkaloids respectively. ADRs were specifically related to Paclitaxel, Cisplatin and Rituximab. The most common adverse effects included; redness, itching, dyspnea and tachycardia. Antihistamines and corticosteroids were most commonly used in treatment of ADRs. The drugs that interacted most with antineoplastics were antibiotics, anticonvulsants and antihypertensives. Conclusion: Although the incidence of ADRs in cancer patients is high, the reporting rate is relatively low. ADRs associated with antineoplastic drugs are serious reactions. Identifying which drugs cause the most ADRs is crucial for prevention, monitoring, and treatment.

28 February 2026 in BALIKESIR HEALTH SCIENCES JOURNAL
Verified
Journal Article
Open access
İSİlhan Sabancilar
İlhan Sabancilar
MYMurat Yolcu
Murat Yolcu
ZOZEYNEP ERDOGMUS OZGEN
ZEYNEP ERDOGMUS OZGEN
ESElif Sumer
Elif Sumer
HMHelin Mercan
Helin Mercan
IYİsMail Yener
İsMail Yener
Objective: Ovarian cancer remains one of the leading causes of mortality among gynecological malignancies. The OVCAR-3 cell line is commonly used as an in-vitro model in studies investigating ovarian cancer pathogenesis and therapeutic strategies. This study aimed to evaluate the cytotoxic effects of whey protein isolate using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and its antioxidant capacity using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging method. Materials and Methods: Buffalo milk was collected from the Guroymak district of Bitlis Province. Whey protein isolate was obtained and subsequently analyzed for antioxidant activity using the DPPH assay. Its anticancer effects were assessed on OVCAR-3 and HUVEC cell lines using the MTT assay. Experimental conditions included eight different concentrations (9.75, 19.50, 39, 78, 156, 312, and 624 µg/mL) together with a negative control group, and treatments were applied for 24 and 48 hours. Results: According to MTT analysis, the highest concentration (624 μg/mL) induced 18.54% cytotoxicity at 24 hours and 41.12% at 48 hours in OVCAR-3 cells (GraphPad analysis). A significant positive correlation was observed between buffalo milk and the resulting whey protein isolate (R² = 0.871, p < 0.05). The DPPH assay demonstrated that whey protein isolated from buffalo milk exhibited notable antioxidant activity, with an IC₅₀ value of 93.64 μg/mL. Conclusion: In this study, whey protein isolate demonstrated measurable antioxidant activity and affected the viability of OVCAR-3 ovarian cancer cells in a dose- and time-dependent manner. The findings suggest that whey protein isolate may warrant further investigation to better understand its potential effects on cancer and normal cells in the context of antioxidant and anticancer research.

19 November 2026 in Biology
Verified
Journal Article
Open access
PDF file
MKMERYEM ŞEYDA KAYA
MERYEM ŞEYDA KAYA
MEMeral Erdinc
Meral Erdinc
ZOZEYNEP ERDOGMUS OZGEN
ZEYNEP ERDOGMUS OZGEN
IKİlker Kelle
İlker Kelle
FAFesih Aktar
Fesih Aktar
MKMehmet Küçüköner
Mehmet Küçüköner
Doxorubicin (DOX) is a commonly used antineoplastic agent whose clinical use is mainly limited by its cardiotoxicity. Since necroptosis has been implicated in DOX-induced cardiotoxicity, this study investigated and compared the protective effects of dabrafenib (Dab), a RIPK3 inhibitor, and necrostatin-1 (Nec-1), a RIPK1 inhibitor, targeting two key components of the necroptotic signaling pathway. Thirty-six male Sprague–Dawley rats were divided into four groups: control, DOX, DOX+Dab, and DOX+Nec-1. Coronary perfusion pressure was assessed in isolated hearts using the Langendorff system, while serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels, cardiac malondialdehyde (MDA) levels, histopathological alterations, and the expression of necroptosis-related proteins were analyzed. DOX treatment significantly increased coronary perfusion pressure, serum CK and LDH levels, cardiac MDA levels, and RIPK1, RIPK3, and mixed lineage kinase domain-like protein (MLKL) expression and induced marked histopathological damage. Both dabrafenib and Nec-1 attenuated these alterations and histopathological damage, although the magnitude of their effects varied across the measured outcomes. No significant differences in serum CK or LDH levels were observed between the two treatment groups. Overall, our findings suggest that dabrafenib may attenuate DOX-induced cardiac injury, although its effects on necroptotic signaling remain to be established.